Clinical Trials Browser

Phase 2 × Solid Tumor × Clear all

NCT05023655 2026-03-17

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Phase 2 Terminated

Other solid neoplasm

Solid Tumor

NCT04617054 2026-01-21

Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion

Phase 2 Terminated

Other solid neoplasm

Solid Tumor

NCT07003321 2025-12-18

A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2 Recruiting

Other solid neoplasm

Solid Tumor

NCT05522491 2025-12-11

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Phase 2 Not yet recruiting

Other solid neoplasm

Solid Tumor

NCT04276376 2025-12-01

ARIANES

Phase 2 Terminated

Other solid neoplasm

Solid Tumor

NCT05119907 2025-11-17

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05642780 2025-10-14

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT07107633 2025-08-06

A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.

Phase 2 Recruiting

Other solid neoplasm

Solid Tumor

NCT04671901 2025-05-28

A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors

Phase 2 Terminated

2 enrolled 4 charts

Other solid neoplasm

Solid Tumor

NCT04827576 2025-05-08

ELEVATELung&UC

Phase 2 Terminated

106 enrolled 22 charts

Other solid neoplasm

Solid Tumor

NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Phase 2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06117540 2024-11-19

A Study of WX390 in Patients With Advanced Solid Tumors

Phase 2 Recruiting

Other solid neoplasm

Solid Tumor

NCT04185831 2024-08-22

MEGALiT

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT06537505 2024-08-05

A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors

Phase 2 Not yet recruiting

Other solid neoplasm

Solid Tumor

NCT03861156 2024-04-09

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

Phase 2 Completed

Other solid neoplasmThoracic

Solid Tumor

NCT03834220 2024-02-07

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

Phase 2 Terminated

63 enrolled 18 charts

Other solid neoplasm

Solid Tumor

NCT04071756 2024-02-07

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

Phase 2 Terminated

8 enrolled 12 charts

Other solid neoplasm

Solid Tumor

NCT04911907 2023-11-08

Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors

Phase 2 Unknown

Other solid neoplasm

Solid Tumor

NCT04346381 2023-09-18

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Phase 2 Completed

Other solid neoplasm

Solid Tumor

NCT05284214 2023-09-15

SALIENT

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT06022289 2023-09-01

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Phase 2 Unknown

Other solid neoplasm

Solid Tumor

NCT05898451 2023-06-12

R-2

Phase 2 Completed

Other solid neoplasm

Solid Tumor

NCT05528406 2022-09-06

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation

Phase 2 Unknown

Other solid neoplasm

Solid Tumor

NCT05512780 2022-08-23

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

Phase 2 Unknown

Other solid neoplasm

Solid Tumor

NCT02447419 2022-06-15

Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors

Phase 2 Completed

Other solid neoplasm

Solid Tumor

NCT05274191 2022-03-10

An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors

Phase 2 Unknown

Other solid neoplasm

Solid Tumor

NCT03865082 2022-02-17

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT03220854 2022-01-10

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

Phase 2 Completed

5 enrolled 12 charts

Other solid neoplasm

Solid Tumor

NCT05097781 2021-10-28

Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients

Phase 2 Unknown

Other solid neoplasm

Solid Tumor

NCT04180384 2021-07-29

A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients

Phase 2 Completed

Other solid neoplasm

Solid Tumor

NCT04832204 2021-04-05

Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases

Phase 2 Unknown

Other solid neoplasm

Solid Tumor

NCT04569916 2020-09-30

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

Phase 2 Unknown

Other solid neoplasm

Solid Tumor

NCT04179656 2019-11-27

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Phase 2 Unknown

Other solid neoplasm

Solid Tumor

NCT02950103 2019-09-30

Efficacy and Safety of Synthetic Phosphoethanolamine in Solid Tumor Patients

Phase 2 Terminated

Other solid neoplasm

Solid Tumor

NCT03147976 2019-08-28

QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT03166176 2019-05-20

TSC1/2_SC

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT03166904 2019-05-20

RICTOR_SC

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT02449538 2017-02-17

Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors

Phase 2 Completed

Other solid neoplasm

Solid Tumor

NCT02656849 2016-07-01

BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT00982657 2015-11-20

A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma

Phase 2 Terminated

34 enrolled 10 charts

Other solid neoplasm

Solid Tumor

NCT02255292 2014-10-02

A Study: Pure CBD as Single-agent for Solid Tumor.

Phase 2 Unknown

Other solid neoplasm

Solid Tumor